Biosidus, Sign

mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry Disease

Published on 08/07/2025 at 18:03 | prnewswire.co.uk

mAbxience United Kingdom England Germany Switzerland Italy Spain Latin America Argentina

View original content:https://www.prnewswire.co.uk/news-releases/mabxience-and-biosidus-sign-cdmo-agreement-for-the-manufacture-of-agalsidase-beta-for-the-treatment-of-fabry-disease-302051912.html

en | DE0005224406 | BIOSIDUS | boerse | 67996864 |